Blog
RSS FeedPosted by Michael Wonder on 03 May 2024
Improved deal signals NICE recommendation of sickle cell treatment voxelotor
3 May 2024 - Around 4,000 people with sickle cell disease could benefit from a new treatment recommended by NICE ...
Posted by Michael Wonder on 06 May 2024
Taysha Gene Therapies announces regenerative medicine advanced therapy designation granted by US FDA for TSHA-102 in Rett syndrome
2 May 2024 - RMAT designation follows FDA’s review of available safety and efficacy data from the first three patients dosed ...
Posted by Michael Wonder on 05 May 2024
PHARMAC and Health NZ weigh up future of COVID-19 vaccines and treatments
3 May 2024 - PHARMAC and Health NZ are weighing up the future direction of COVID-19 vaccinations and treatments in ...
Posted by Michael Wonder on 05 May 2024
Vyndamax (tafamidis) PBS listed for adult patients with wild type or hereditary transthyretin amyloid cardiomyopathy with New York Heart Association class I-II heart failure
4 May 2024 - The availability of Vyndamax on the PBS provides subsidised access to a once daily oral single ...
Posted by Michael Wonder on 04 May 2024
Wegovy (semaglutide injection) available in Canada
2 May 2024 - First and only Health Canada approved once weekly medication for chronic weight management ...
Posted by Michael Wonder on 03 May 2024
Agenda for the May 2024 PBAC meeting
3 May 2024 - The agenda for next week's PBAC meeting is now available. Robyn Ward's first meeting as the ...
Posted by Michael Wonder on 03 May 2024
NHS rolls out ‘life-changing’ treatment for thousands with sickle cell disease
3 May 2024 - Thousands of patients with sickle cell disorder are to be offered a new “life-changing” treatment on ...
Posted by Michael Wonder on 03 May 2024
Enhertu to get insurance coverage for metastatic breast/stomach cancer from April
29 March 2024 - Starting next month, health insurance benefits will be applied to treating metastatic breast and gastric cancers ...
Posted by Michael Wonder on 02 May 2024
Amolyt Pharma granted FDA fast track designation for eneboparatide for the treatment of hypoparathyroidism
2 May 2024 - Amolyt Pharma today announced that eneboparatide, its lead therapeutic peptide candidate in Phase 3 development for the ...
Posted by Michael Wonder on 02 May 2024
ICER to assess treatment for Epstein-Barr virus positive post-transplant lymphoproliferative disease
2 May 2024 - Report will be subject of New England CEPAC meeting in November 2024; draft scoping document open ...
Posted by Michael Wonder on 02 May 2024
Labcorp receives FDA approval for first companion diagnostic for use with Pfizer's newly approved gene therapy to treat patients with haemophilia B
29 April 2024 - Labcorp today announced the U.S. FDA has approved its nAbCyte Anti-AAVRh74var HB-FE Assay, a companion diagnostic to ...
Posted by Michael Wonder on 02 May 2024
US FDA approves high concentration, citrate-free formulation of Cyltezo (adalimumab-adbm) injection, Boehringer Ingelheim's interchangeable biosimilar to Humira
1 May 2024 - Boehringer Ingelheim announced today that the US FDA has approved the high concentration, citrate-free formulation of ...
Posted by Michael Wonder on 02 May 2024
PHARMAC funding will not stretch to new medicines - chief executive
29 April 2024 - A multi-million dollar budget boost for PHARMAC will only keep the lights on, doctors and patient ...
Posted by Michael Wonder on 02 May 2024
CADTH is now Canada’s Drug Agency
1 May 2024 - As of today, we will adopt Canada’s Drug Agency (CDA-AMC) as our new operating name. ...
Posted by Michael Wonder on 02 May 2024
PHARMAC publishes agenda from the 15-16 February 2024 PTAC meeting
1 May 2024 - The outcomes from the February 2024 PTAC meeting are now available. ...